Medicare Enrolled

Dr. Michael Gurevitch, M.D

Pulmonary Disease · Pasadena, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
39 CONGRESS ST, Pasadena, CA 91105
6264860187
In practice since 2006 (19 years)
NPI: 1629016894 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gurevitch from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gurevitch? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Gurevitch

Dr. Michael Gurevitch is a pulmonary disease specialist in Pasadena, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Gurevitch performed 1,388 Medicare services across 747 unique beneficiaries.

Between the years covered by Open Payments, Dr. Gurevitch received a total of $7,235 from 38 pharmaceutical and/or device companies across 284 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Gurevitch is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 28% volume in CA $7,235 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,388
Medicare services
Top 28% in CA for pulmonary disease
747
Unique beneficiaries
$61
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~73 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Airflow rate measurement test
A test that measures the rate of airflow. This procedure assesses how quickly air moves.
575 $32 $67
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
540 $100 $171
Chest X-ray, 1 view
An X-ray image of the chest taken from a single angle. This imaging test is used to visualize the structures within the chest cavity.
184 $23 $41
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
38 $64 $116
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
31 $131 $262
Home visit, established patient, moderate complexity
A home visit for an established patient involving moderate medical decision making. The visit requires at least 40 minutes of time if time is used to determine the level of service.
20 $103 $198
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$7,235
Total received (2018-2024)
Avg $1,034/year across 7 years
Top 22% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
38
Companies
284
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,372 (88.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$525 (7.3%)
Other
Charitable contributions, space rental, and other categories
$338 (4.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,075
2023
$589
2022
$760
2021
$519
2020
$867
2019
$2,154
2018
$1,271

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Fisher & Paykel Healthcare Limited
$525
Teleflex LLC
$163
Abbott Laboratories
$147
GlaxoSmithKline, LLC.
$132
AstraZeneca Pharmaceuticals LP
$44
Mylan Specialty L.P.
$39
United Therapeutics Corporation
$26
Top 3 companies account for 77.6% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$1,756
Boehringer Ingelheim Pharmaceuticals, Inc.
$694
AstraZeneca Pharmaceuticals LP
$679
Fisher & Paykel Healthcare Limited
$525
Philips Electronics North America Corporation
$450
Fisher & Paykel Healthcare Inc
$338
Abbott Laboratories
$280
Actelion Pharmaceuticals US, Inc.
$280
Mylan Specialty L.P.
$266
Grifols USA, LLC
$206
Sunovion Pharmaceuticals Inc.
$195
Teleflex LLC
$163
ADVANCED RESPIRATORY, INC
$140
Circassia Pharmaceuticals Inc
$135
Amgen Inc.
$117
Regeneron Healthcare Solutions, Inc.
$110
Lilly USA, LLC
$109
Allergan Inc.
$85
Covidien LP
$83
Electromed, Inc.
$78
Genentech USA, Inc.
$63
Mallinckrodt Enterprises LLC
$59
Advanced Respiratory, Inc
$54
United Therapeutics Corporation
$52
Otsuka America Pharmaceutical, Inc.
$39
Teva Pharmaceuticals USA, Inc.
$32
Shionogi Inc
$31
Merck Sharp & Dohme Corporation
$29
Becton, Dickinson and Company
$26
Bayer HealthCare Pharmaceuticals Inc.
$24
PORTOLA PHARMACEUTICALS, INC.
$24
Horizon Therapeutics plc
$19
Janssen Pharmaceuticals, Inc
$19
Nabriva Therapeutics, plc
$19
Theravance Biopharma, Inc.
$16
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$15
E.R. Squibb & Sons, L.L.C.
$14
PFIZER INC.
$13
Top 3 companies account for 43.2% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (8876) Vest Therapy Und · ACTHAR · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · ASMANEX · AVYCAZ · Adempas · BEVYXXA · BOSENTAN · BREO · BREO ELLIPTA · BREZTRI · BROVANA · CINQAIR · DUPIXENT · Dymista · ELIQUIS · Edge · Esbriet · FARXIGA · FASENRA · FISHER & PAYKEL HEALTHCARE · FREESTYLE LIBRE 3 · Fetroja · LONHALA MAGNAIR · Life 2000 Ventilation System · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ProAir Digihaler · Prolastin-C · Prolastin-C Liquid · RAYOS · REXULTI · Repatha · Respiratoriy Care Undiv · SAMSCA · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · TRELEGY ELLIPTA · TRULICITY · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · The VitalCough System · Trilogy 100 · UPTRAVI · UROLIFT · Utibron · VIBATIV · Wellcentive Undiv · XARELTO · XIFAXAN · Xenleta · Xolair · YUPELRI · Yupelri · ZERBAXA · inCourage · superDimension
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a pulmonary disease specialist in Pasadena?
Compare pulmonary diseases in the Pasadena area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary diseases within 10 mi
263
Per 100K population
2.7
County median income
$87,760
Nearest hospital
GLENDALE ADVENTIST MEDICAL CENTER
3.1 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Gurevitch is a clinical cardiology specialist, with above-average Medicare volume (top 28% in CA), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Gurevitch experienced with airflow rate measurement test?
Based on Medicare claims data, Dr. Gurevitch performed 575 airflow rate measurement test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gurevitch receive payments from pharmaceutical companies?
Yes. Dr. Gurevitch received a total of $7,235 from 38 companies across 284 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gurevitch's costs compare to other pulmonary diseases in Pasadena?
Dr. Gurevitch's average Medicare payment per service is $61. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gurevitch) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →